Nasdaq · CIK 0001393434
OCUL OCULAR THERAPEUTIX, INC
Insider trading from SEC Form 4. Last filing 6 d ago. Close $7.54 on Oct 9, 2026, +10% from the 52-week low and -53% from the high.
Last 90 days
Net insider value
-$158k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$158k by 3 insiders
Insiders on file
17
with a Form 4 at this company
Price and insider trades, last year
OCULOct 9, 2026 · close 7.54
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at OCULAR THERAPEUTIX, INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 11Weak | Jeffrey S. Heier Chief Scientific Officer sell | $77k 10,869 shares | -3% | +1% from low-57% from high | |
| 11Weak | Peter Kaiser Chief Development Officer sell | $70k 9,990 shares | -4% | +1% from low-57% from high | |
| 20Weak | Donald Notman Chief Operating Officer sell | $11k 1,099 shares | -0% | - | |
| 21Weak | Pravin Dugel See Remarks sell | $166k 20,056 shares | -1% | +42% from low-48% from high | |
| 15Weak | Jeffrey S. Heier Chief Scientific Officer sell | $25k 3,057 shares | -1% | +42% from low-48% from high | |
| 10Weak | Peter Kaiser Chief Development Officer sell | $23k 2,810 shares | -1% | +42% from low-48% from high | |
| 10Weak | Sanjay Nayak Chief Strategy Officer sell | $15k 1,759 shares | -1% | +42% from low-48% from high | |
| 46Moderate | Richard L Lindstrom Md director buy | $461k 60,229 shares | +32% | +31% from low-52% from high | |
| 15Weak | Nadia Waheed Chief Medical Officer sell | $27k 3,510 shares | -1% | +31% from low-52% from high | |
| 35Weak | Pravin Dugel See Remarks sell | $1.1M 124,882 shares | -4% | +53% from low-44% from high | |
| 20Weak | Sanjay Nayak Chief Strategy Officer sell | $94k 10,348 shares | -3% | +53% from low-44% from high | |
| 45Moderate | Donald Notman Chief Operating Officer sell | $103k 11,446 shares | -3% | +53% from low-44% from high | |
| 18Weak | Nadia Waheed Chief Medical Officer sell | $71k 7,863 shares | -2% | +53% from low-44% from high | |
| 45Moderate | Donald Notman Chief Operating Officer sell | $101k 11,490 shares | -3% | +54% from low-43% from high | |
| 23Weak | Pravin Dugel See Remarks sell | $235k 19,530 shares | -1% | +104% from low-11% from high | |
| 16Weak | Jeffrey S. Heier Chief Scientific Officer sell | $42k 3,469 shares | -1% | +104% from low-11% from high | |
| 16Weak | Peter Kaiser Chief Development Officer sell | $36k 3,007 shares | -2% | +104% from low-11% from high | |
| 10Weak | Sanjay Nayak Chief Strategy Officer sell | $23k 1,878 shares | -1% | +104% from low-11% from high | |
| 14Weak | Namrata Saroj Chief Business Officer sell | $278k 25,865 shares | -13% | +82% from low-21% from high | |
| 26Weak | Todd Anderman Chief Legal Officer sell | $137k 11,132 shares | -11% | +101% from low-12% from high | |
| 20Weak | Jeffrey S. Heier Chief Scientific Officer sell | $116k 10,502 shares | -4% | +87% from low-19% from high | |
| 20Weak | Peter Kaiser Chief Development Officer sell | $106k 9,653 shares | -5% | +87% from low-19% from high | |
| 30Weak | Donald Notman See Remarks sell | $13k 1,066 shares | -0% | +114% from low0% from high | |
| 23Weak | Pravin Dugel See Remarks sell | $259k 21,494 shares | -1% | +100% from low-6% from high | |
| 16Weak | Jeffrey S. Heier Chief Scientific Officer sell | $37k 3,063 shares | -1% | +100% from low-6% from high | |
| 16Weak | Peter Kaiser Chief Development Officer sell | $36k 3,011 shares | -1% | +100% from low-6% from high | |
| 10Weak | Sanjay Nayak Chief Strategy Officer sell | $23k 1,885 shares | -1% | +100% from low-6% from high | |
| 20Weak | Nadia Waheed Chief Medical Officer sell | $112k 13,861 shares | -6% | +37% from low-29% from high | |
| 21Weak | Pravin Dugel See Remarks sell | $152k 21,219 shares | -1% | +23% from low-36% from high | |
| 10Weak | Jeffrey S. Heier Chief Scientific Officer sell | $22k 3,024 shares | -1% | +23% from low-36% from high | |
| 10Weak | Peter Kaiser Chief Development Officer sell | $21k 2,974 shares | -1% | +23% from low-36% from high | |
| 10Weak | Sanjay Nayak Chief Strategy Officer sell | $13k 1,862 shares | -1% | +23% from low-36% from high | |
| 34Weak | Richard L Lindstrom Md director buy | $70k 10,000 shares | +6% | +26% from low-35% from high | |
| 21Weak | Pravin Dugel See Remarks sell | $148k 21,475 shares | -1% | - | |
| 10Weak | Jeffrey S. Heier Chief Scientific Officer sell | $21k 3,061 shares | -1% | - | |
| 10Weak | Peter Kaiser Chief Development Officer sell | $21k 3,009 shares | -1% | - | |
| 22Weak | Pravin Dugel See Remarks sell | $186k 20,680 shares | -3% | - | |
| 15Weak | Jeffrey S. Heier Chief Scientific Officer sell | $27k 2,948 shares | -1% | - | |
| 15Weak | Peter Kaiser Chief Development Officer sell | $26k 2,897 shares | -1% | - | |
| 10Weak | Sanjay Nayak Chief Strategy Officer sell | $16k 1,814 shares | -1% | - |
Transactions
The last 84 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Peter Kaiser Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -9,990 | $7.05 | $70k | 254,388 | 6 d ago |
| Oct 2, 2026 | Jeffrey S. Heier Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -10,869 | $7.05 | $77k | 307,457 | 6 d ago |
| Aug 31, 2026 | Donald Notman Chief Operating Officer | SOpen-market sale Common Stock | -1,099 | $10.24 | $11k | 366,529 | 40 d ago |
| Feb 23, 2026 | Pravin Dugel See Remarks | SOpen-market sale Common Stock10b5-1 | -20,056 | $8.28 | $166k | 3,013,022 | Feb 25, 2026 |
| Feb 23, 2026 | Jeffrey S. Heier Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,057 | $8.28 | $25k | 323,368 | Feb 25, 2026 |
| Feb 23, 2026 | Peter Kaiser Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -2,810 | $8.28 | $23k | 269,108 | Feb 25, 2026 |
| Feb 23, 2026 | Sanjay Nayak Chief Strategy Officer | SOpen-market sale Common Stock10b5-1 | -1,759 | $8.28 | $15k | 330,653 | Feb 25, 2026 |
| Feb 20, 2026 | Richard L Lindstrom Md director | POpen-market purchase Common Stock | +60,229 | $7.66 | $461k | 246,933 | Feb 24, 2026 |
| Feb 20, 2026 | Nadia Waheed Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -3,510 | $7.74 | $27k | 314,907 | Feb 24, 2026 |
| Feb 12, 2026 | Pravin Dugel See Remarks | SOpen-market sale Common Stock10b5-1 | -124,882 | $9.04 | $1.1M | 3,033,078 | Feb 17, 2026 |
| Feb 12, 2026 | Sanjay Nayak Chief Strategy Officer | SOpen-market sale Common Stock10b5-1 | -10,348 | $9.04 | $94k | 332,412 | Feb 17, 2026 |
| Feb 12, 2026 | Donald Notman Chief Operating Officer | SOpen-market sale Common Stock | -11,446 | $9.04 | $103k | 366,356 | Feb 17, 2026 |
| Feb 12, 2026 | Nadia Waheed Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -7,863 | $9.04 | $71k | 318,417 | Feb 17, 2026 |
| Feb 2, 2026 | Donald Notman Chief Operating Officer | SOpen-market sale Common Stock | -5,455 | $9.14 | $50k | 383,837 | Feb 4, 2026 |
| Feb 4, 2026 | Donald Notman Chief Operating Officer | SOpen-market sale Common Stock | -6,035 | $8.54 | $52k | 377,802 | Feb 4, 2026 |
| Jan 21, 2026 | David Wayne Robinson Global CCO | AGrant or award Common Stock | +136,000 | $0.00 | $0 | 136,000 | Jan 26, 2026 |
| Jan 21, 2026 | David Wayne Robinson Global CCO | AGrant or award Stock Option (Right to Buy)derivative | +416,000 | $0.00 | $0 | 416,000 | Jan 26, 2026 |
| Jan 20, 2026 | Jason Shand Robins Interim CFO | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jan 22, 2026 |
| Jan 2, 2026 | Namrata Saroj Chief Business Officer | AGrant or award Common Stock | +79,112 | $0.00 | $0 | 254,620 | Jan 6, 2026 |
| Jan 2, 2026 | Nadia Waheed Chief Medical Officer | AGrant or award Common Stock | +79,112 | $0.00 | $0 | 326,280 | Jan 6, 2026 |
| Jan 2, 2026 | Donald Notman See Remarks | AGrant or award Common Stock | +79,112 | $0.00 | $0 | 389,292 | Jan 6, 2026 |
| Jan 2, 2026 | Sanjay Nayak Chief Strategy Officer | AGrant or award Common Stock | +64,900 | $0.00 | $0 | 342,760 | Jan 6, 2026 |
| Jan 2, 2026 | Peter Kaiser Chief Development Officer | AGrant or award Common Stock | +79,112 | $0.00 | $0 | 271,918 | Jan 6, 2026 |
| Jan 2, 2026 | Steve Lawrence Meyers Chief Commercial Officer | AGrant or award Common Stock | +64,900 | $0.00 | $0 | 217,628 | Jan 6, 2026 |
| Jan 2, 2026 | Todd Anderman Chief Legal Officer | AGrant or award Common Stock | +64,900 | $0.00 | $0 | 152,468 | Jan 6, 2026 |
| Jan 2, 2026 | Jeffrey S. Heier Chief Scientific Officer | AGrant or award Common Stock | +79,112 | $0.00 | $0 | 326,425 | Jan 6, 2026 |
| Jan 2, 2026 | Steve Lawrence Meyers Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +197,650 | $0.00 | $0 | 197,650 | Jan 6, 2026 |
| Jan 2, 2026 | Namrata Saroj Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +240,932 | $0.00 | $0 | 240,932 | Jan 6, 2026 |
| Jan 2, 2026 | Nadia Waheed Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +240,932 | $0.00 | $0 | 240,932 | Jan 6, 2026 |
| Jan 2, 2026 | Todd Anderman Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +197,650 | $0.00 | $0 | 197,650 | Jan 6, 2026 |
| Jan 2, 2026 | Donald Notman See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +240,932 | $0.00 | $0 | 240,932 | Jan 6, 2026 |
| Jan 2, 2026 | Sanjay Nayak Chief Strategy Officer | AGrant or award Stock Option (Right to Buy)derivative | +197,650 | $0.00 | $0 | 197,650 | Jan 6, 2026 |
| Jan 2, 2026 | Jeffrey S. Heier Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +240,932 | $0.00 | $0 | 240,932 | Jan 6, 2026 |
| Jan 2, 2026 | Peter Kaiser Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +240,932 | $0.00 | $0 | 240,932 | Jan 6, 2026 |
| Nov 24, 2025 | Pravin Dugel See Remarks | SOpen-market sale Common Stock10b5-1 | -19,530 | $12.04 | $235k | 3,157,960 | Nov 26, 2025 |
| Nov 24, 2025 | Jeffrey S. Heier Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,469 | $12.04 | $42k | 245,940 | Nov 26, 2025 |
| Nov 24, 2025 | Peter Kaiser Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -3,007 | $12.02 | $36k | 191,433 | Nov 26, 2025 |
| Nov 24, 2025 | Sanjay Nayak Chief Strategy Officer | SOpen-market sale Common Stock10b5-1 | -1,878 | $12.04 | $23k | 277,860 | Nov 26, 2025 |
| Nov 26, 2025 | Pravin Dugel See Remarks | GGift Common Stockindirect: By spouse10b5-1 | -49,754 | $0.00 | $0 | 0 | Nov 26, 2025 |
| Nov 26, 2025 | Pravin Dugel See Remarks | GGift Common Stockindirect: By Pravin Dugel 2024 Irrevocable Trust10b5-1 | +49,754 | $0.00 | $0 | 300,115 | Nov 26, 2025 |
| Nov 5, 2025 | Namrata Saroj Chief Business Officer | SOpen-market sale Common Stock10b5-1 | -25,865 | $10.74 | $278k | 174,135 | Nov 7, 2025 |
| Oct 8, 2025 | Todd Anderman Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -11,132 | $12.34 | $137k | 87,568 | Oct 10, 2025 |
| Oct 2, 2025 | Jeffrey S. Heier Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -10,502 | $11.04 | $116k | 249,409 | Oct 6, 2025 |
| Oct 2, 2025 | Peter Kaiser Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -9,653 | $11.03 | $106k | 194,440 | Oct 6, 2025 |
| Sep 9, 2025 | Pravin Dugel See Remarks | GGift Common Stock | -49,754 | $0.00 | $0 | 3,177,490 | Sep 11, 2025 |
| Sep 9, 2025 | Pravin Dugel See Remarks | GGift Common Stockindirect: By spouse | +49,754 | $0.00 | $0 | 49,754 | Sep 11, 2025 |
| Sep 2, 2025 | Donald Notman See Remarks | SOpen-market sale Common Stock | -1,066 | $12.43 | $13k | 308,807 | Sep 4, 2025 |
| Aug 25, 2025 | Pravin Dugel See Remarks | SOpen-market sale Common Stock10b5-1 | -21,494 | $12.04 | $259k | 3,227,244 | Aug 27, 2025 |
| Aug 25, 2025 | Jeffrey S. Heier Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,063 | $12.04 | $37k | 259,911 | Aug 27, 2025 |
| Aug 25, 2025 | Peter Kaiser Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -3,011 | $12.04 | $36k | 204,093 | Aug 27, 2025 |
| Aug 25, 2025 | Sanjay Nayak Chief Strategy Officer | SOpen-market sale Common Stock10b5-1 | -1,885 | $12.04 | $23k | 279,738 | Aug 27, 2025 |
| Aug 12, 2025 | Nadia Waheed Chief Medical Officer | AGrant or award Common Stock | +40,363 | $0.00 | $0 | 247,168 | Aug 14, 2025 |
| Aug 12, 2025 | Nadia Waheed Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +122,923 | $0.00 | $0 | 122,923 | Aug 14, 2025 |
| Apr 28, 2025 | Pravin Dugel See Remarks | GGift Common Stock | -200,332 | $0.00 | $0 | 3,298,767 | Aug 13, 2025 |
| Jun 12, 2025 | Pravin Dugel See Remarks | GGift Common Stock | -50,029 | $0.00 | $0 | 3,248,738 | Aug 13, 2025 |
| Aug 11, 2025 | Pravin Dugel See Remarks | GGift Common Stockindirect: By Pravin Dugel 2024 Irrevocable Trust | +250,361 | $0.00 | $0 | 250,361 | Aug 13, 2025 |
| Jun 11, 2025 | Pravin Dugel See Remarks | AGrant or award Performance Stock Option (Right to Buy)derivative | +2,750,000 | $0.00 | $0 | 2,750,000 | Jun 13, 2025 |
| Jun 11, 2025 | Adrienne L Graves director | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 50,000 | Jun 13, 2025 |
| Jun 11, 2025 | Seung Suh Hong director | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 46,933 | Jun 13, 2025 |
| Jun 11, 2025 | Richard L Lindstrom Md director | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 143,145 | Jun 13, 2025 |
| Jun 11, 2025 | Merilee Raines director | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 46,933 | Jun 13, 2025 |
| Jun 11, 2025 | Charles M Warden director | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 86,464 | Jun 13, 2025 |
| Jun 11, 2025 | Leslie J. Williams director | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 51,433 | Jun 13, 2025 |
| Jun 11, 2025 | Charles M Warden director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 13, 2025 |
| Jun 11, 2025 | Merilee Raines director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 13, 2025 |
| Jun 11, 2025 | Leslie J. Williams director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 13, 2025 |
| Jun 11, 2025 | Seung Suh Hong director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 13, 2025 |
| Jun 11, 2025 | Adrienne L Graves director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 13, 2025 |
| Jun 11, 2025 | Richard L Lindstrom Md director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 13, 2025 |
| Jun 2, 2025 | Nadia Waheed Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -13,861 | $8.05 | $112k | 206,805 | Jun 3, 2025 |
| May 23, 2025 | Pravin Dugel See Remarks | SOpen-market sale Common Stock10b5-1 | -21,219 | $7.18 | $152k | 3,499,099 | May 27, 2025 |
| May 23, 2025 | Jeffrey S. Heier Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,024 | $7.18 | $22k | 262,974 | May 27, 2025 |
| May 23, 2025 | Peter Kaiser Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -2,974 | $7.17 | $21k | 207,104 | May 27, 2025 |
| May 23, 2025 | Sanjay Nayak Chief Strategy Officer | SOpen-market sale Common Stock10b5-1 | -1,862 | $7.17 | $13k | 281,623 | May 27, 2025 |
| May 8, 2025 | Richard L Lindstrom Md director | POpen-market purchase Common Stock | +10,000 | $6.96 | $70k | 172,704 | May 12, 2025 |
| Feb 24, 2025 | Pravin Dugel See Remarks | SOpen-market sale Common Stock10b5-1 | -21,475 | $6.87 | $148k | 3,520,318 | Feb 26, 2025 |
| Feb 24, 2025 | Jeffrey S. Heier Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,061 | $6.87 | $21k | 265,998 | Feb 26, 2025 |
| Feb 24, 2025 | Peter Kaiser Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -3,009 | $6.87 | $21k | 210,078 | Feb 26, 2025 |
| Feb 11, 2025 | Pravin Dugel See Remarks | AGrant or award Common Stock | +1,250,000 | $0.00 | $0 | 2,041,793 | Feb 13, 2025 |
| Feb 11, 2025 | Pravin Dugel See Remarks | AGrant or award Common Stock | +1,500,000 | $0.00 | $0 | 3,541,793 | Feb 13, 2025 |
| Nov 25, 2024 | Pravin Dugel See Remarks | SOpen-market sale Common Stock10b5-1 | -20,680 | $9.01 | $186k | 791,793 | Nov 27, 2024 |
| Nov 25, 2024 | Jeffrey S. Heier Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -2,948 | $9.01 | $27k | 269,059 | Nov 27, 2024 |
| Nov 25, 2024 | Peter Kaiser Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -2,897 | $9.01 | $26k | 213,087 | Nov 27, 2024 |
| Nov 25, 2024 | Sanjay Nayak Chief Strategy Officer | SOpen-market sale Common Stock10b5-1 | -1,814 | $9.00 | $16k | 174,380 | Nov 27, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Todd AndermanChief Legal Officer
- Pravin DugelSee Remarks
- Adrienne L Gravesdirector
- Jeffrey S. HeierChief Scientific Officer
- Seung Suh Hongdirector
- Peter KaiserChief Development Officer
- Richard L Lindstrom Mddirector
- Steve Lawrence MeyersChief Commercial Officer
- Sanjay NayakChief Strategy Officer
- Donald NotmanChief Operating Officer
- Merilee Rainesdirector
- Jason Shand RobinsInterim CFO
- David Wayne RobinsonGlobal CCO
- Namrata SarojChief Business Officer
- Nadia WaheedChief Medical Officer
- Charles M Wardendirector
- Leslie J. Williamsdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.